Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 14.71 USD -0.07% Market Closed
Market Cap: 1.2B USD

Operating Margin
Viridian Therapeutics Inc

-111 591.1%
Current
-52 138.8%
Average
-5%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111 591.1%
=
Operating Profit
-337m
/
Revenue
302k

Operating Margin Across Competitors

Viridian Therapeutics Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

In the bustling frontier of biotechnology, Viridian Therapeutics Inc. emerges as a dynamic player, carving a niche within the field of precision medicine. Founded with the mission to revolutionize treatment regimens for serious diseases, Viridian channels its expertise into developing innovative therapies for rare and underserved conditions. The company primarily focuses on advancing its pipeline of monoclonal antibodies to combat and manage thyroid eye disease (TED), a rare autoimmune disorder. By leveraging cutting-edge research and development, Viridian harnesses its scientific prowess to translate complex biological insights into promising therapeutic candidates. The meticulous process involves extensive clinical trials and regulatory navigation, ensuring that only robustly tested solutions reach the medical community. Viridian's business model hinges on strategic collaborations, licensing agreements, and scientific innovation. It navigates the intricate landscape of biotechnology by forging alliances with research institutions and industry leaders to bolster its R&D capabilities. These collaborations not only expedite the drug development process but also provide opportunities for licensing and milestone payments, supplementing early-stage revenue. Ultimately, the true engine of Viridian’s financial performance lies in successfully bringing its therapeutic offerings to the market. In this competitive sphere, generating revenue manifests through the commercialization of their approved treatments, and as these therapies gain traction in medical circles, the company anticipates a revenue stream through product sales and partnerships, cementing its position as a leader in targeted therapies for rare conditions.

VRDN Intrinsic Value
67.47 USD
Undervaluation 78%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111 591.1%
=
Operating Profit
-337m
/
Revenue
302k
What is the Operating Margin of Viridian Therapeutics Inc?

Based on Viridian Therapeutics Inc's most recent financial statements, the company has Operating Margin of -111 591.1%.

Back to Top